ADAR1 Capital Management, LLC 13F holdings, Q3 2025
Holdings as of September 30, 2025 · filings on SEC EDGAR · latest filing →
ADAR1 Capital Management, LLC disclosed 199 US equity positions worth $1.0bn in its Q3 2025 13F filing. The largest position was ABVX at 11.4% of the reported book, followed by KROS and PTGX. Against the Q2 2025 filing, it opened 7 new positions, added to 23 and reduced 14 among the top 50 holdings.
What did ADAR1 Capital Management, LLC own in Q3 2025? Top 50 positions
| # | Stock | Sector | Weight | Value | Shares | Δ shares | vs Q2 2025 |
|---|---|---|---|---|---|---|---|
| 1 | ABVX ABIVAX SA | 11.4% | $114.7m | 1,350,826 | -56% | reduced | |
| 2 | KROS KEROS THERAPEUTICS INC | Healthcare | 8.4% | $85.3m | 5,389,264 | 0% | held |
| 3 | PTGX PROTAGONIST THERAPEUTICS INC | Healthcare | 6.5% | $65.7m | 989,182 | 4% | added |
| 4 | ROIV ROIVANT SCIENCES LTD | Healthcare | 5.0% | $50.6m | 3,347,501 | 72% | added |
| 5 | BOXX EA SERIES TRUST | 3.8% | $38.4m | 337,125 | 0% | held | |
| 6 | SPY SPDR S&P 500 ETF TR | 3.6% | $36.4m | 54,684 | 141% | added | |
| 7 | IMVT IMMUNOVANT INC | Healthcare | 3.6% | $36.1m | 2,241,753 | 319% | added |
| 8 | ETNBGBP 89BIO INC | 3.1% | $31.1m | 2,113,153 | 141% | added | |
| 9 | ZLAB ZAI LAB LTD | Healthcare | 2.9% | $29.4m | 868,780 | 2% | added |
| 10 | CYTK CYTOKINETICS INC | Healthcare | 2.8% | $28.5m | 518,921 | -11% | reduced |
| 11 | SEPN SEPTERNA INC | 2.2% | $22.1m | 1,176,491 | 39% | added | |
| 12 | PROTHENA CORP PLC | 1.4% | $14.3m | 1,469,098 | -56% | reduced | |
| 13 | BBIO BRIDGEBIO PHARMA INC | Healthcare | 1.4% | $14.2m | 273,414 | 5% | added |
| 14 | ABUS ARBUTUS BIOPHARMA CORP | Healthcare | 1.3% | $13.2m | 2,903,226 | 3% | added |
| 15 | RAPT RAPT THERAPEUTICS INC | 1.3% | $13.1m | 507,771 | -35% | reduced | |
| 16 | CTMX CYTOMX THERAPEUTICS INC | Healthcare | 1.3% | $12.9m | 4,045,414 | 31% | added |
| 17 | BIL SPDR SERIES TRUST | 1.2% | $12.4m | 135,585 | 0% | held | |
| 18 | AMLX AMYLYX PHARMACEUTICALS INC | Healthcare | 1.2% | $11.8m | 866,202 | -28% | reduced |
| 19 | BIOA BIOAGE LABS INC | 1.1% | $11.1m | 1,880,073 | -3% | reduced | |
| 20 | MNPR MONOPAR THERAPEUTICS INC | 1.1% | $10.6m | 129,999 | 29% | added | |
| 21 | CRNXGBP CRINETICS PHARMACEUTICALS IN | 1.0% | $10.3m | 248,368 | 368% | added | |
| 22 | LXEO LEXEO THERAPEUTICS INC | Healthcare | 1.0% | $10.2m | 1,531,953 | 956% | added |
| 23 | CGON CG ONCOLOGY INC | Healthcare | 1.0% | $10.0m | 248,917 | -52% | reduced |
| 24 | TSHA TAYSHA GENE THERAPIES INC | Healthcare | 0.9% | $9.3m | 2,835,680 | -6% | reduced |
| 25 | REGN REGENERON PHARMACEUTICALS | Healthcare | 0.9% | $8.8m | 15,700 | 367% | added |
| 26 | IONS IONIS PHARMACEUTICALS INC | Healthcare | 0.9% | $8.8m | 133,818 | -10% | reduced |
| 27 | JANX JANUX THERAPEUTICS INC | Healthcare | 0.8% | $8.6m | 351,032 | 465% | added |
| 28 | IKT INHIBIKASE THERAPEUTICS INC | 0.8% | $8.5m | 5,247,603 | 2% | added | |
| 29 | IVVD INVIVYD INC | Healthcare | 0.8% | $8.1m | 7,370,987 | – | new |
| 30 | METSERA INC | 0.8% | $8.0m | 152,521 | – | new | |
| 31 | EQ EQUILLIUM INC | 0.8% | $8.0m | 5,559,988 | – | new | |
| 32 | PERCEPTIVE CAP SOLUTIONS COR | 0.8% | $7.9m | 750,000 | 0% | held | |
| 33 | QURE UNIQURE NV | 0.8% | $7.8m | 133,316 | – | new | |
| 34 | PCVX VAXCYTE INC | Healthcare | 0.8% | $7.7m | 213,064 | 117% | added |
| 35 | RZLT REZOLUTE INC | 0.8% | $7.7m | 815,975 | -18% | reduced | |
| 36 | XENE XENON PHARMACEUTICALS INC | Healthcare | 0.8% | $7.6m | 189,098 | -27% | reduced |
| 37 | ASND ASCENDIS PHARMA A/S | Healthcare | 0.7% | $7.2m | 36,345 | 2492% | added |
| 38 | SVRA SAVARA INC | Healthcare | 0.7% | $7.1m | 1,988,288 | -45% | reduced |
| 39 | SRPT SAREPTA THERAPEUTICS INC | Healthcare | 0.7% | $6.7m | 349,807 | 66% | added |
| 40 | RVMD REVOLUTION MEDICINES INC | Healthcare | 0.6% | $6.5m | 139,136 | 4% | added |
| 41 | AA MISSION ACQUISITION CORP | 0.6% | $6.1m | 578,359 | 0% | held | |
| 42 | BBOT BRIDGEBIO ONCOLOGY THERAPEUT | 0.6% | $5.8m | 501,228 | – | new | |
| 43 | VRNA VERONA PHARMA PLC | 0.5% | $5.5m | 51,450 | 81% | added | |
| 44 | OAKTREE ACQUISITION CORP III | 0.5% | $5.5m | 516,482 | 0% | held | |
| 45 | TEVA TEVA PHARMACEUTICAL INDS LTD | Healthcare | 0.5% | $5.4m | 267,816 | -23% | reduced |
| 46 | RYTM RHYTHM PHARMACEUTICALS INC | Healthcare | 0.5% | $5.0m | 49,571 | 9% | added |
| 47 | ATAI LIFE SCIENCES NV | 0.5% | $4.8m | 913,242 | – | new | |
| 48 | UTHR UNITED THERAPEUTICS CORP DEL | Healthcare | 0.5% | $4.7m | 11,200 | – | new |
| 49 | VKTX VIKING THERAPEUTICS INC | Healthcare | 0.5% | $4.6m | 175,919 | 159% | added |
| 50 | BBIO BRIDGEBIO PHARMA INC | 0.4% | $4.4m | 45,000 | -99% | reduced |
Weights are shares of the reported long US equity book (options excluded). Values are as filed, normalised to whole dollars. Share changes compare against the immediately preceding filing only.